Jefferies and Leerink Swann are the bookrunners; Piper Jaffray assists
By Devika Patel
Knoxville, Tenn., Feb. 5 - uniQure BV said it priced its $91.8 million initial public offering of stock with a $13.77 million greenshoe. The deal was announced Jan. 2.
The company will sell 5.4 million ordinary shares at $17.00 per share.
Jefferies LLC and Leerink Partners LLC are the joint bookrunning managers.
Settlement is expected Feb. 10.
Proceeds will be used to build and equip the company's manufacturing facility in Lexington, Mass., for clinical development of Glybera and other products, clinical trials, working capital and general corporate purposes, including debt repayment and potential acquisitions.
The Amsterdam company develops gene therapy products. The company intends to list its common stock on the Nasdaq stock exchange under the symbol "QURE."
| Issuer: | uniQure BV
|
| Issue: | Ordinary stock
|
| Amount: | $91.8 million
|
| Greenshoe: | $13.77 million
|
| Shares: | 5.4 million
|
| Price: | $17.00
|
| Warrants: | No
|
| Bookrunners: | Jefferies LLC and Leerink Partners LLC
|
| Lead manager: | Piper Jaffray & Co.
|
| Announcement date: | Jan. 2
|
| Pricing date: | Feb. 5
|
| Settlement date: | Feb. 10
|
| Stock symbol: | Nasdaq: QURE
|
© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere.
For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.
